Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In collaboration with Cambodian authorities, MORU are running the Village Drama Against Malaria project for the third year. The project, which runs in 10 remote villages in March 2018, aims to create awareness about malaria prevention and early treatment.

Children in a play

In collaboration with Cambodian authorities and a local Cambodia theatre group, MORU are running the Village Drama Against Malaria project in Siem Pang district, Stung Treng province. This is the third year we are running this project. The project runs from 25th Feb to 29th March 2018 and will be in 10 villages, some of them very remote farming villages with close to the border with Laos along the Sikong river. Most of these villages are remote and populated by Lao and other ethnic minority peoples. 

The aim of the project is to create awareness about malaria prevention and early treatment; and infant vaccination using art and theater as engagement tools and leveraging traditional ethnic arts.

The theatre group goes from one village to another conducting art and theatre workshops with village children and young people. They also invite villagers to share their traditional tools, costumes. arts and dances. On the third evening, there is a public performance at the village square where there are games, singing competitions, malaria quizzes, and a comedy sketch about malaria – performed by village children.

The project is led by Nou Sanann (Public Engagement Officer) with support from Pich Kunthea, Tom Peto, Rupam Tripura, James Callery and Phaik Yeong Cheah, and is funded by a Wellcome Trust Provision for Public Engagement grant (supplement).

Similar stories

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Community and Public Engagement at KWTRP

KWTRP Public Engagement

KWTRP initial community and public engagement strategy was developed in 2005 with three goals: build understanding and trust between researchers and communities, enhance ethical conduct of research, and disseminate research findings to promote uptake into policy. Our programme has since developed and now includes engagement with media, radio programme, media engagement workshops, various meetings and forums, and a fully-fledged school engagement programme that was awarded the 2019 Oxford VC Public Engagement with Research Award.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU OCGHR Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU OCGHR

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU OCGHR Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.